Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Revvity Inc.(RVTY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RVTY
11/04/2026: RVTY (4-star) is a STRONG-BUY. BUY for 123 days. Simulated Profits (60.73%). Updated daily EoD!
Revvity Inc. is a specialized life sciences and diagnostics company focused on providing advanced laboratory instrumentation, genetic screening, and research software. The company has successfully pivoted from a broader conglomerate to a focused, high-margin player in the precision medicine space. Its primary investment story centers on organic growth in its core lab workflows and strategic expansion into digital health technologies. Key risks include intense competition from larger industry peers and exposure to fluctuations in pharmaceutical R&D spending. Investors interested in healthcare innovation may find it a strong candidate, though they should monitor quarterly growth in its software and diagnostics segments to gauge execution success.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Revvity is positioned to capture growth in the specialized life sciences and precision medicine sectors. |
| Momentum investor | Mixed fit | Momentum depends on clear signals of organic growth acceleration post-rebranding. |
| Value investor | Mixed fit | The valuation is often tied to high-growth expectations in the biotech space. |
| Dividend investor | Weak fit | The company focuses on growth and capital deployment rather than high dividend yield. |
| Low-risk investor | Mixed fit | Exposure to healthcare R&D spending introduces inherent volatility compared to defensive consumer stocks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is subject to fluctuations driven by sector-specific R&D trends. |
| Valuation risk | Medium | Growth expectations are already priced into the stock, leaving little room for earnings misses. |
| Competition risk (Life Sciences) | High | Intense competition from well-capitalized giants like TMO limits pricing power. |
| Business quality | Strong | Revvity holds a reputable, high-tech, and defensible position in specialized scientific markets. |
| Dividend income | Low | The payout is not the primary driver of investor return. |
| Execution risk | Medium | Successfully integrating and scaling software services is crucial for long-term margins. |
Price Behavior
Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 27.39% | Avg. Invested days 52 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/04/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 17.79B USD | Price to earnings Ratio 70.86 | 1Y Target Price 149.87 |
Price to earnings Ratio 70.86 | 1Y Target Price 149.87 | ||
Volume (30-day avg) 2.0M shares | Beta 1.09 | 52 Weeks Range 81.13 - 171.74 | Updated Date 11/04/2026 |
52 Weeks Range 81.13 - 171.74 | Updated Date 11/04/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.25 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Sciences | Instruments, reagents, and software for drug discovery and academic research. | Selling the 'picks and shovels' for the drug discovery market. |
| Diagnostics | Clinical laboratory tests for reproductive health and genomics. | Providing essential health testing services to hospitals and labs. |
| Geography | Global sales across North America, Europe, and Asia-Pacific. | Broad international footprint reduces reliance on any single country's health spending. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-03 | When Before Market | Estimate 1.29 | Actual 1.38 |
Profitability
Profit Margin 8.16% | Operating Margin (TTM) 17.05% |
Management Effectiveness
Return on Assets (TTM) 2.37% | Return on Equity (TTM) 3.21% |
Valuation
Trailing PE 70.86 | Forward PE 27.78 | Enterprise Value 20.56B | Price to Sales(TTM) 6.11 |
Enterprise Value 20.56B | Price to Sales(TTM) 6.11 | ||
Enterprise Value to Revenue 7.06 | Enterprise Value to EBITDA 26.63 | Shares Outstanding 111.59M | Shares Floating 102.49M |
Shares Outstanding 111.59M | Shares Floating 102.49M | ||
Percent Insiders 0.26 | Percent Institutions 104.17 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.